BPI 9016

Drug Profile

BPI 9016

Alternative Names: BPI-9016; BPI-9016M

Latest Information Update: 14 Oct 2016

Price : $50

At a glance

  • Originator Betta Pharmaceuticals Co Ltd
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 10 Oct 2016 Betta Pharmaceuticals plans a phase Ib/II trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, First-line therapy) in China (PO) (NCT02929290)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top